NeoPharm CO., LTD. Statistics

Total Valuation

NeoPharm CO., LTD. has a market cap or net worth of KRW 180.92 billion. The enterprise value is 66.25 billion.

Market Cap	180.92B
Enterprise Value	66.25B

Important Dates

The next estimated earnings date is Friday, February 7, 2025.

Earnings Date	Feb 7, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

NeoPharm CO., LTD. has 15.25 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	15.25M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	1.28%
Owned by Institutions (%)	12.10%
Float	8.79M

Valuation Ratios

The trailing PE ratio is 8.31 and the forward PE ratio is 6.90.

PE Ratio	8.31
Forward PE	6.90
PS Ratio	1.65
PB Ratio	1.09
P/TBV Ratio	1.07
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 2.39, with an EV/FCF ratio of -11.37.

EV / Earnings	2.97
EV / Sales	0.59
EV / EBITDA	2.39
EV / EBIT	2.66
EV / FCF	-11.37

Financial Position

The company has a current ratio of 10.99, with a Debt / Equity ratio of 0.00.

Current Ratio	10.99
Quick Ratio	9.77
Debt / Equity	0.00
Debt / EBITDA	0.02
Debt / FCF	-0.11
Interest Coverage	585.76

Financial Efficiency

Return on equity (ROE) is 13.76% and return on invested capital (ROIC) is 9.57%.

Return on Equity (ROE)	13.76%
Return on Assets (ROA)	8.82%
Return on Capital (ROIC)	9.57%
Revenue Per Employee	633.90M
Profits Per Employee	126.18M
Employee Count	177
Asset Turnover	0.64
Inventory Turnover	3.48

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -50.38% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-50.38%
50-Day Moving Average	15,781.00
200-Day Moving Average	23,003.00
Relative Strength Index (RSI)	35.51
Average Volume (20 Days)	66,603

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NeoPharm CO., LTD. had revenue of KRW 112.20 billion and earned 22.33 billion in profits. Earnings per share was 1,427.89.

Revenue	112.20B
Gross Profit	67.89B
Operating Income	24.92B
Pretax Income	28.27B
Net Income	22.33B
EBITDA	27.69B
EBIT	24.92B
Earnings Per Share (EPS)	1,427.89

Full Income Statement

Balance Sheet

The company has 115.33 billion in cash and 662.75 million in debt, giving a net cash position of 114.67 billion or 7,516.99 per share.

Cash & Cash Equivalents	115.33B
Total Debt	662.75M
Net Cash	114.67B
Net Cash Per Share	7,516.99
Equity (Book Value)	170.51B
Book Value Per Share	10,901.09
Working Capital	130.89B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 16.17 billion and capital expenditures -21.99 billion, giving a free cash flow of -5.83 billion.

Operating Cash Flow	16.17B
Capital Expenditures	-21.99B
Free Cash Flow	-5.83B
FCF Per Share	-381.91

Full Cash Flow Statement

Margins

Gross margin is 60.51%, with operating and profit margins of 22.21% and 19.91%.

Gross Margin	60.51%
Operating Margin	22.21%
Pretax Margin	25.20%
Profit Margin	19.91%
EBITDA Margin	24.68%
EBIT Margin	22.21%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 375.00, which amounts to a dividend yield of 3.16%.

Dividend Per Share	375.00
Dividend Yield	3.16%
Dividend Growth (YoY)	7.14%
Years of Dividend Growth	1
Payout Ratio	26.26%
Buyback Yield	n/a
Shareholder Yield	3.16%
Earnings Yield	12.04%
FCF Yield	-3.22%

Dividend Details

Stock Splits

The last stock split was on October 30, 2024. It was a forward split with a ratio of 2.

Last Split Date	Oct 30, 2024
Split Type	Forward
Split Ratio	2

Scores

NeoPharm CO., LTD. has an Altman Z-Score of 11.87.

Altman Z-Score	11.87
Piotroski F-Score	n/a